Entasis Therap Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ENTASIS THERAP
ENTASIS THERAP has two approved drugs.
There are ten US patents protecting ENTASIS THERAP drugs.
There are one hundred and twenty-seven patent family members on ENTASIS THERAP drugs in forty-five countries.
Summary for Entasis Therap
| International Patents: | 127 |
| US Patents: | 10 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
Drugs and US Patents for Entasis Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Entasis Therap | XACDURO (COPACKAGED) | durlobactam sodium; durlobactam sodium; sulbactam sodium | POWDER;INTRAVENOUS | 216974-001 | May 23, 2023 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| Entasis Therap | NUZOLVENCE | zoliflodacin | FOR SUSPENSION;ORAL | 219491-001 | Dec 12, 2025 | RX | Yes | Yes | 8,658,641 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Entasis Therap | NUZOLVENCE | zoliflodacin | FOR SUSPENSION;ORAL | 219491-001 | Dec 12, 2025 | RX | Yes | Yes | 9,839,641 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Entasis Therap Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Philippines | 12017500852 | ⤷ Start Trial |
| Croatia | P20200401 | ⤷ Start Trial |
| Mexico | 354627 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
